Our results revealed that the combination of EGFR-TKI plus anti-VEGFR contributed to prolonging PFS compared to EGFR-TKI alone but did not impact the OS in advanced NSCLC treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.